Jaguar Health Inc

JAGX06 Dec 2024
Healthcare
$1
+0.01 (+0.90%)
Lowest Today
$0.96
Highest Today
$1.03
Today’s Open
$1
Prev. Close
$0.98
52 Week High
$21.6
52 Week Low
$0.9
To Invest in Jaguar Health Inc

Jaguar Health Inc

Healthcare
JAGX06 Dec 2024
+0.01 (+0.90%)
1M
3M
6M
1Y
5Y
Low
$0.96
Day’s Range
High
$1.03
0.96
52 Week Low
$0.9
52-Week Range
52 Week High
$21.6
0.9
1 Day
-
1 Week
-5.99%
1 month return
-6.44%
3 month return
-13.54%
6 month return
-74.71%
1 Year return
-94.94%
3 Years return
-99.98%
5 Years return
-99.98%
10 Years return
-
Institutional Holdings
Geode Capital Management, LLC
0.69
Vanguard Group Inc
0.5
Vanguard Institutional Extnd Mkt Idx Tr
0.5
Fidelity Extended Market Index
0.45
Goldman Sachs Group Inc
0.37
UBS Group AG
0.29
Perritt Ultra MicroCap
0.21

Market Status

Fundamentals
Market Cap
11.56 mln
PB Ratio
0.88
PE Ratio
0.05
Enterprise Value
32.56 mln
Total Assets
50.76 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Organisation
Jaguar Health Inc
Employees
49
Industry
Biotechnology
CEO
Ms. Lisa A. Conte
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities